drugset
Drugs / ASM-024
last change Dec 2014 re-read 3 minutes ago

ASM-024

targets CHRM1, CHRM2, CHRM3, CHRNA7 via inhibition

Developed for
asthma · allergic asthma · chronic obstructive pulmonary disease
Investigated by
Asmacure

Trials 4

today NCT01855230 · Ph 2 NCT01793298 · Ph 1/2 NCT01190826 · Ph 2 NCT01092403 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT01793298 Mar 2013 → Mar 2014 asthma Asmacure Terminated No outcome recorded
Phase 23 trials
Phase 2 NCT01855230 Aug 2013 → Oct 2014 chronic obstructive pulmonary disease Asmacure Completed No outcome recorded
Phase 2 NCT01190826 Aug 2010 → Dec 2011 asthma Asmacure Completed No outcome recorded
Phase 2 NCT01092403 Apr 2010 → Dec 2011 allergic asthma Asmacure Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as ASM-024 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01190826 ↗
3

NCT01793298 ↗

NCT01092403 ↗

NCT01855230 ↗
Action Inhibit “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL3707249 ↗
2

“Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3707249 ↗

“Muscarinic acetylcholine receptor M2 antagonist” CHEMBL3707249 ↗
Route Inhaled “once daily by inhalation” NCT01092403 ↗
Target CHRM1 “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL3707249 ↗
Target CHRM2 “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL3707249 ↗
Target CHRM3 “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3707249 ↗
Target CHRNA7 “Neuronal acetylcholine receptor protein alpha-7 subunit modulator” CHEMBL3707249 ↗